Hoth Therapeutics Secures Exclusive Patent License from VA and Emory University to Tackle Obesity and Related Diseases

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...

December 27, 2024 | Friday | News
AusperBio Therapeutics Secures $73M Series B Funding to Advance Targeted Therapies for Chronic Hepatitis B

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...

December 27, 2024 | Friday | News
Bristol Myers Squibb’s Sotyktu Achieves Key Phase 3 Success in Psoriatic Arthritis, Demonstrating Significant Efficacy

 Bristol Myers Squibb (NYSE: BMY) announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evalua...

December 24, 2024 | Tuesday | News
CStone Pharmaceuticals Submits Clinical Trial Application for CS2009, a Tri-Specific Antibody Targeting PD-1, VEGF, and CTLA-4 for Solid Tumors

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

December 23, 2024 | Monday | News
FDA Approves Zepbound® (Tirzepatide) as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the fir...

December 21, 2024 | Saturday | News
FDA Approves BRAFTOVI® Combination Therapy for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuxi...

December 21, 2024 | Saturday | News
Regeneron Announces Positive Phase 2 Results for Factor XI Antibodies REGN7508 and REGN9933 in Preventing Venous Thromboembolism

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Fa...

December 20, 2024 | Friday | News
Shuttle Pharmaceuticals and UCSF Collaborate in the U.S. to Advance Theranostic Innovations for Prostate Cancer

Shuttle Pharmaceuticals Holdings, Inc.  a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer ...

December 20, 2024 | Friday | News
European Commission Grants Orphan Medicinal Product Designation to Mitapivat for Sickle Cell Disease

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

December 19, 2024 | Thursday | News
Viatris Announces Positive Phase 2b CARE Study Results for Cenerimod in Adults with Moderate-to-Severe Lupus

 Viatris Inc. (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of ceneri...

December 19, 2024 | Thursday | News
Roche Secures CE Mark for cobas® Mass Spec Solution, Bringing Automated Clinical Mass Spectrometry to Routine Laboratories Worldwide

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 ana...

December 19, 2024 | Thursday | News
A2A Pharmaceuticals Advances Clinical Trials for AO-252, TACC3 Inhibitor, in Ovarian, TNBC, and Endometrial Cancers

A2A Pharmaceuticals, Inc. ("A2A" or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies...

December 18, 2024 | Wednesday | News
Regeneron’s EYLEA HD® Achieves Key Milestone in Phase 3 QUASAR Trial for Macular Edema Due to Retinal Vein Occlusion

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (af...

December 18, 2024 | Wednesday | News
Eli Lilly’s Kisunla™ (Donanemab) Approved by China’s NMPA for Early Symptomatic Alzheimer’s Disease

Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...

December 18, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close